期刊文献+

抗精神病药物对精神分裂症患者体重的影响及护理干预 被引量:2

抗精神病药物对精神分裂症患者体重的影响及护理干预
下载PDF
导出
摘要 目的探讨精神分裂症患者服用抗精神病药物期间实施护理干预对改善患者体重指数(BMI)增加的影响。方法选择住院治疗的精神分裂症患者520例,随机均分为干预组和对照组,监测并比较两组患者用药前、后体重指数变化情况。结果用药后干预组患者体重指数较用药前显著增加(P<0.05),对照组患者体重指数增加较用药前极显著(P<0.01),用药后组间比较体重指数差异有显著性(P<0.05)。结论有效的护理干预可降低精神分裂症患者体重指数增加的幅度,提高患者的用药依从性,降低体重增加引起的心血管疾病、糖尿病、乳腺癌等并发症的风险。 Objective To investigate the influence of the changing circumstances on body mass index,who with nursing intervention during the period of using drugs.Methods Selected totally 520 schizophrenia patients,randomly and equally divided into the intervention group and the control group,monitor and compare the changing circumstances on body mass index.Results The body mass index in the intervention group was increased significantly compared with before treating(P0.05),and the body mass index in the control group was increased very significantly compared with before treating(P0.01),there was significant differences between the two groups after medicine treatment(P0.05).Conclusion Nursing interventions were effectively given to schizophrenic patients during the medicine treatment could reduce the amplitude of body mass index,improve the patients' medication compliance,reduce the risk of cardiovascular disease or diabetes or breast cancer by causing weight gain.
出处 《当代医学》 2011年第7期1-2,共2页 Contemporary Medicine
关键词 精神分裂症 体重指数 氯氮平 护理干预 Schizophrenia Body mass index(BMI) Clozapine Nursing intervention
  • 相关文献

参考文献7

二级参考文献38

  • 1郭珍,李春波,吴文源,李华芳,王克勋.利培酮及氯氮平对治疗精神分裂症患者血清Leptin浓度影响的初步研究[J].上海精神医学,2002,14(1):23-25. 被引量:5
  • 2刘燕,李华芳,王慧芳,王克勋,高哲石,顾牛范.氯氮平和利培酮对精神分裂症病人体重、瘦素及脂代谢的影响[J].中国新药与临床杂志,2004,23(9):579-582. 被引量:13
  • 3金秋莲.100例精神分裂症再入院诱因分析[J].上海精神医学,2002,14(4):223-225. 被引量:10
  • 4[1]Allison DB,Mentore JL,Heo M,et al.Weight gain associated with conventional and newer antipsychotics.Eur Neuropsychopharmacol,1998,8(suppl 2):S216-S217.
  • 5[2]Bina KG,Cincotta AH.Dopaminergic agonists normalise elevated hypothalamic neuropeptide Y and corticotropin-releasing hormone,body weight gain,and hyperglycemia in ob/ob mice.Neuroendocrinology,2000,71:68-78.
  • 6[3]Thompson J,Thomas N,Singleton A,et al.D2 dopamine receptor gene(DRD2) Taq I A polymorphism:reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele.Pharmacogenetics,1997,7:479-484.
  • 7[4]Thomas GN,Tomlinson B,Critchlev JA.Modulation of blood pressure and obesity with the dopamine D2 receptor gene TaqI polymorphism.Hypertension,2000,36:177-182.
  • 8[5]Grandy DK,Zhang Y,Civelli O.PCR detection of the TaqA RFLP at the DRD2 locus.Hum Mol Gene,1993,2:2197.
  • 9[6]Ko GT,Tang J,Chan JC,et al.Lower BMI cut-off value to define obesity in Hong Kong Chinese:an analysis based on body fat assessment by bioelectrical impedance.Br J Nutr,2001,85:239-242.
  • 10[7]Masellis M,Basile VS,Ozdemir V,et al.Pharmacogenetics of antipsychotic treatment:lessons learned from clozapine.Biol Psychiatry,2000,47:253-266.

共引文献28

同被引文献10

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部